Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intranasal Oxytocin in the Treatment of Autism

Trial Profile

Intranasal Oxytocin in the Treatment of Autism

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oxytocin (Primary)
  • Indications Autistic disorder
  • Focus Therapeutic Use

Most Recent Events

  • 23 Oct 2015 Biomarkers information updated
  • 11 Jul 2012 Additional lead trial centres added as reported by ClinicalTrials.gov record.
  • 11 Jul 2012 Actual end date (April 2012) added as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top